Routine Gene Testing Advised To Guide Colorectal Cancer Treatment
This article was originally published in The Gray Sheet
Executive Summary
The American Society of Clinical Oncology Jan. 13 recommended that physicians treating metastatic colorectal cancer patients who are candidates for drugs such as ImClone's Erbitux (cetuximab) or Amgen's Vectibix (panitumumab) first be tested for KRASgene mutations
You may also be interested in...
Lab Group Makes Economic Case For Gene Testing Industry
The laboratory industry, facing policy pressures, commissioned a study by Battelle Memorial Institute that finds that genetic testing is adding thousands of jobs and $16.5 billion annually to the U.S. economy.
DxS Plans PMA For Companion Test To Amgen Colorectal Cancer Drug
Personalized medicine company DxS is preparing a PMA application for a companion diagnostic to Amgen's colorectal cancer drug Vectibix, supported by clinical utility data from a recent Amgen-sponsored clinical trial, according to DxS CEO Stephen Little
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.